Payment overview · 2025
General Payments
$12,552.93
100 reported records · 26 companies
Healthcare provider profile · identity verified
Paul Michael Arnold, M.D.
Allopathic & Osteopathic Physicians|Urology · DAVENPORT, FL · NPI 1841294501
Verified facts
What the public records show
CMS Open Payments records show Paul Michael Arnold, M.D. received $12,552.93 in general payments during 2025 across 100 reported records.
Richard Wolf Medical Instruments Corp. accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Richard Wolf Medical Instruments Corp. | Unresolved — no canonical attribution shown | $5,023.14 | 40.0% | 4 | 2025 |
| Verathon Inc. | Unresolved — no canonical attribution shown | $1,500.00 | 11.9% | 1 | 2025 |
| Olympus America Inc. | Unresolved — no canonical attribution shown | $916.30 | 7.3% | 12 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $588.66 | 4.7% | 13 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$489.56 | 3.9% | 2 | 2025 |
| Procept Biorobotics Corporation | Unresolved — no canonical attribution shown | $452.57 | 3.6% | 4 | 2025 |
| Endo USA, Inc. | Unresolved — no canonical attribution shown | $343.12 | 2.7% | 14 | 2025 |
| UROGEN PHARMA, INC. | Unresolved — no canonical attribution shown | $329.69 | 2.6% | 5 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $314.23 | 2.5% | 9 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $300.30 | 2.4% | 3 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $290.18 | 2.3% | 4 | 2025 |
| Ambu Inc. | Unresolved — no canonical attribution shown | $281.71 | 2.2% | 3 | 2025 |
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $248.94 | 2.0% | 6 | 2025 |
| SRS Medical Systems, Inc. | Unresolved — no canonical attribution shown | $211.24 | 1.7% | 2 | 2025 |
| Dornier MedTech America, Inc | Unresolved — no canonical attribution shown | $209.43 | 1.7% | 1 | 2025 |
| Edap Technomed Inc | Unresolved — no canonical attribution shown | $194.54 | 1.6% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $142.34 | 1.1% | 1 | 2025 |
| Valencia Technologies Corporation | Unresolved — no canonical attribution shown | $140.65 | 1.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $136.14 | 1.1% | 4 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $135.00 | 1.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $72.07 | 0.6% | 1 | 2025 |
| Profound Medical Corp. | Unresolved — no canonical attribution shown | $67.81 | 0.5% | 1 | 2025 |
| KARL STORZ Endoscopy-America | Unresolved — no canonical attribution shown | $66.66 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.51 | 0.4% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $28.66 | 0.2% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $24.48 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,907.32 | 96 |
| Consulting Fee | $4,395.32 | 3 |
| Travel and Lodging | $2,250.29 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NPD Clinical Study Normalized: npd clinical study |
Device | Verathon Inc. | $1,500.00 | 1 | 2025 |
Source payment records
|
|||||
| iTIND System Normalized: itind system |
Device | Olympus America Inc. | $671.64 | 10 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $489.56 | 2 | 2025 |
Source payment records
|
|||||
| AQUABEAM ROBOTIC SYSTEM Normalized: aquabeam robotic system |
Device | Procept Biorobotics Corporation | $452.57 | 4 | 2025 |
Source payment records
|
|||||
| XIAFLEX Normalized: xiaflex |
Biological | Endo USA, Inc. | $343.12 | 14 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $314.23 | 9 | 2025 |
Source payment records
|
|||||
| TISSEEL Normalized: tisseel |
Biological | Baxter Healthcare | $300.30 | 3 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $290.18 | 4 | 2025 |
Source payment records
|
|||||
| CT3000 Pro Base Unit Normalized: ct3000 pro base unit |
Device | SRS Medical Systems, Inc. | $211.24 | 2 | 2025 |
Source payment records
|
|||||
| UroCuff-DC Disposable, Single Normalized: urocuff dc disposable single |
Device | SRS Medical Systems, Inc. | $211.24 | 2 | 2025 |
Source payment records
|
|||||
| Dornier MedTech Normalized: dornier medtech |
Device | Dornier MedTech America, Inc | $209.43 | 1 | 2025 |
Source payment records
|
|||||
| FOCAL ONE Normalized: focal one |
Device | Edap Technomed Inc | $194.54 | 2 | 2025 |
Source payment records
|
|||||
| HD CAMERA HEAD Normalized: hd camera head |
Device | Olympus America Inc. | $184.15 | 1 | 2025 |
Source payment records
|
|||||
| LithoVue Normalized: lithovue |
Device | Boston Scientific Corporation | $174.92 | 1 | 2025 |
Source payment records
|
|||||
| JELMYTO Normalized: jelmyto |
Drug | UROGEN PHARMA, INC. | $169.76 | 4 | 2025 |
Source payment records
|
|||||
| AVEED Normalized: aveed |
Biological | Endo USA, Inc. | $163.13 | 10 | 2025 |
Source payment records
|
|||||
| Altis Normalized: altis |
Device | COLOPLAST CORP | $162.94 | 2 | 2025 |
Source payment records
|
|||||
| Bulkamid Normalized: bulkamid |
Device | Boston Scientific Corporation | $144.84 | 1 | 2025 |
Source payment records
|
|||||
| Axonics Normalized: axonics |
Device | Boston Scientific Corporation | $143.84 | 7 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $142.34 | 1 | 2025 |
Source payment records
|
|||||
| eCoin Device Kit Normalized: ecoin device kit |
Device | Valencia Technologies Corporation | $140.65 | 2 | 2025 |
Source payment records
|
|||||
| EVARREST Normalized: evarrest |
Biological | Ethicon US, LLC | $138.42 | 1 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $138.42 | 1 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon US, LLC | $138.42 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $93.83 | 2 | 2025 |
Source payment records
|
|||||
| Titan Normalized: titan |
Device | COLOPLAST CORP | $86.00 | 4 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $74.58 | 3 | 2025 |
Source payment records
|
|||||
| 1788 Normalized: 1788 |
Medical Supply | Stryker Corporation | $72.07 | 1 | 2025 |
Source payment records
|
|||||
| Tulsa-Pro Normalized: tulsa pro |
Device | Profound Medical Corp. | $67.81 | 1 | 2025 |
Source payment records
|
|||||
| HOPKINS Normalized: hopkins |
Device | KARL STORZ Endoscopy-America | $66.66 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $61.56 | 1 | 2025 |
Source payment records
|
|||||
| Gyrus ACMI Normalized: gyrus acmi |
Device | Olympus America Inc. | $60.51 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $45.51 | 2 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| General - Kidney Stone Disease Normalized: general kidney stone disease |
Device | Boston Scientific Corporation | $28.23 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| EDEX Normalized: edex |
Drug | Endo USA, Inc. | $10.17 | 1 | 2025 |
Source payment records
|
|||||
| LITHOCLAST Normalized: lithoclast |
Device | Boston Scientific Corporation | $3.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 154 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 45 |
| Bicalutamide | Bicalutamide | 55 | 27 |
| Trelstar | Triptorelin Pamoate | 40 | 29 |
| Finasteride | Finasteride | 34 | 13 |
| Cephalexin | Cephalexin | 33 | 23 |
| Estradiol | Estradiol | 31 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | 31 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $12,552.93 · 100 records | Richard Wolf Medical Instruments Corp. | 1788, AMS 700, AQUABEAM ROBOTIC SYSTEM, AVEED, Altis, Axonics, Bulkamid, CT3000 Pro Base Unit, Da Vinci Surgical System, Dornier MedTech, EDEX, EVARREST, FOCAL ONE, GEMTESA, GRAFIX PL, General - Kidney Stone Disease, Gyrus ACMI, HD CAMERA HEAD, HOPKINS, INTERSTIM, Indigo System, Integra, Integra Dermal Regeneration Template, JELMYTO, LITHOCLAST, LithoVue, NPD Clinical Study, ORGOVYX, PLUVICTO, PRIMATRIX, PROVENGE, STRATAFIX, SURGICEL NU-KNIT, TISSEEL, Titan, Tulsa-Pro, UroCuff-DC Disposable, Single, VISTASEAL, XIAFLEX, eCoin Device Kit, iTIND System | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error